SETD2 and renal carcinoma: 33,153 differentially methylated CpGs were identified upon comparing SETD2 mutated and SETD2 control renal cancers (BH-adjusted p-value < 0.05), with 10,549 CpGs hypomethylated in SETD2 cases and 22,604 CpGs hypermethylated CpGs.